Cerebral Vasospasm After Aneurysmal Subarachnoid Hemorrhage and Traumatic Brain Injury
- 804 Downloads
Cerebral vasospasm (cVSP) consists of the vasoconstriction of large and small intracranial vessels which can lead to cerebral hypoperfusion, and in extreme cases, delayed ischemic deficits with stroke. While most commonly observed after aneurysmal subarachnoid hemorrhage (aSAH), cVSP can also occur after traumatic brain injury (TBI) as we have described in detail in this review. For the past decades, the research attention has focused on cVSP because of its association with delayed cerebral ischemia, which is the largest contributor of morbidity and mortality after aSAH. New discoveries in the cVSP pathophysiology involving multifactorial complex cascades and pathways pose new targets for therapeutic interventions in the prevention and treatment of cVSP. The goal of this review is to demonstrate the commonalities and differences in epidemiology and pathophysiology of both aSAH and TBI-associated cVSP, and highlight the more recently discovered pathways of cVSP. Finally, the latest cVSP surveillance methods and treatment options are illustrated.
KeywordsCerebral vasospasm Angiographic vasospasm Delayed cerebral ischemia Traumatic brain injury Subarachnoid hemorrhage Traumatic subarachnoid hemorrhage Blast injury Treatment Aneurysmal subarachnoid hemorrhage
Compliance with Ethics Guidelines
Conflict of Interest
Susanne Muehlschlegel has received grant support from the American Heart Association.
Saef Izzy declares that he has no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with animal subjects performed by any of the authors. With regard to the authors’ research cited in this paper, all procedures were followed in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 2000 and 2008.
References and Recommended Reading
Papers of particular interest, published recently have been highlighted as: • Of importance •• Of major importance
- 1.••Connolly Jr ES, Rabinstein AA, Carhuapoma JR, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/american Stroke Association. Stroke; J Cereb Circul. 2012;43:1711–37These are the most updated AHA guidelines for the care of SAH patients..CrossRefGoogle Scholar
- 18.Gonzalez NR, Boscardin WJ, Glenn T, Vinuela F, Martin NA. Vasospasm probability index: a combination of transcranial doppler velocities, cerebral blood flow, and clinical risk factors to predict cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2007;107:1101–12.PubMedCrossRefGoogle Scholar
- 20.••Diringer MN, Bleck TP, Claude Hemphill 3rd J, et al. Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society's Multidisciplinary Consensus Conference. Neurocritical care. 2011;15:211–40This is a multidisciplinary guideline about the critical care management of SAH with an extensive review of the SAH treatment literature..PubMedCrossRefGoogle Scholar
- 48.ClinicalTrials.gov. Simvastatin in Aneurysmal Subarachnoid Haemorrhage (STASH) a Multicentre Randomised Controlled Clinical Trial. 2013.Google Scholar
- 53.•Woitzik J, Dreier JP, Hecht N, et al. Delayed cerebral ischemia and spreading depolarization in absence of angiographic vasospasm after subarachnoid hemorrhage. Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 2012;32:203–12Interesting, albeit small study in SAH patients revealing that DCI can occur in the absence of cVSP but may be due to spreading depolorizations..CrossRefGoogle Scholar
- 55.Lauritzen M, Dreier JP, Fabricius M, Hartings JA, Graf R, Strong AJ. Clinical relevance of cortical spreading depression in neurological disorders: migraine, malignant stroke, subarachnoid and intracranial hemorrhage, and traumatic brain injury. Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 2011;31:17–35.CrossRefGoogle Scholar
- 56.••Hartings JA, Bullock MR, Okonkwo DO, et al. Spreading depolarisations and outcome after traumatic brain injury: a prospective observational study. Lancet Neurol. 2011;10:1058–64An intriguing, large study in TBI patients that shows that spreading depolorizations are associated with worse clinical outcomes after TBI, without proving causality..PubMedCrossRefGoogle Scholar
- 60.Washington CW, Zipfel GJ. Participants in the International Multi-disciplinary Consensus Conference on the Critical Care Management of Subarachnoid H. Detection and monitoring of vasospasm and delayed cerebral ischemia: a review and assessment of the literature. Neurocrit Care. 2011;15:312–7.PubMedCrossRefGoogle Scholar
- 73.von Helden A, Schneider GH, Unterberg A, Lanksch WR. Monitoring of jugular venous oxygen saturation in comatose patients with subarachnoid haemorrhage and intracerebral haematomas. Acta Neurochir Suppl. 1993;59:102–6.Google Scholar
- 75.Dorhout Mees SM, Rinkel GJ, Feigin VL, et al. Calcium antagonists for aneurysmal subarachnoid haemorrhage. The Cochrane database of systematic reviews 2007:CD000277.Google Scholar
- 85.ClinicalTrials.gov. Safety Study of Dantrolene to Treat Cerebral Vasospasm After Subarachnoid Hemorrhage. 2013. www.ClinicalTrials.gov
- 89.Zwienenberg-Lee M, Hartman J, Rudisill N, et al. Effect of prophylactic transluminal balloon angioplasty on cerebral vasospasm and outcome in patients with Fisher grade III subarachnoid hemorrhage: results of a phase II multicenter, randomized, clinical trial. Stroke; J Cereb Circul. 2008;39:1759–65.CrossRefGoogle Scholar
- 90.Vergouwen MD, Meijers JC, Geskus RB, et al. Biologic effects of simvastatin in patients with aneurysmal subarachnoid hemorrhage: a double-blind, placebo-controlled randomized trial. Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 2009;29:1444–53.CrossRefGoogle Scholar
- 92.••Macdonald RL, Higashida RT, Keller E, et al. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet neurology. 2011;10:618–25This is a Phase III trial reporting the absence of efficacy of clazosentan in SAH..PubMedCrossRefGoogle Scholar
- 93.•Macdonald RL, Higashida RT, Keller E, et al. Randomised trial of clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid hemorrhage undergoing surgical clipping (CONSCIOUS-2). Acta Neurochir Suppl. 2013;115:27–31This is the second negative trial of clazosentan in SAH..PubMedGoogle Scholar